

# Hanneke Wm Van Laarhoven

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8878954/publications.pdf>

Version: 2024-02-01

416  
papers

14,371  
citations

34105

52  
h-index

36028

97  
g-index

425  
all docs

425  
docs citations

425  
times ranked

18341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Narrative recognition and identification: a qualitative pilot study into reading literary texts with advanced cancer patients. <i>Journal of Cancer Survivorship</i> , 2022, 16, 531-541.	2.9	4
2	Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2022, 48, 348-355.	1.0	8
3	Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. <i>Gastric Cancer</i> , 2022, 25, 22-32.	5.3	15
4	The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. <i>Hpb</i> , 2022, 24, 443-451.	0.3	5
5	Muslim doctors and decision making in palliative care: a discourse analysis. <i>Mortality</i> , 2022, 27, 289-306.	0.5	2
6	Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-391.	1.6	13
7	Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. <i>Journal of Pathology</i> , 2022, 256, 282-296.	4.5	11
8	Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study. <i>Cancer Science</i> , 2022, , .	3.9	7
9	This is what life with cancer looks like: exploring experiences of adolescent and young adults with cancer using two visual approaches. <i>Supportive Care in Cancer</i> , 2022, 30, 3353-3361.	2.2	4
10	Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. <i>Hpb</i> , 2022, 24, 1433-1442.	0.3	8
11	Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study. <i>Acta Oncologica</i> , 2022, 61, 545-552.	1.8	7
12	A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	3.2	4
13	A population-based study in synchronous <i>versus</i> metachronous metastatic esophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210855.	3.2	2
14	Treatment decision-making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study. <i>Cancer Medicine</i> , 2022, , .	2.8	1
15	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. <i>Frontiers in Oncology</i> , 2022, 12, 839779.	2.8	9
16	Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe). <i>European Journal of Cancer</i> , 2022, 165, 125-135.	2.8	22
17	Co-creative art processes with patients: A theoretical framework and qualitative study among artists. <i>PLoS ONE</i> , 2022, 17, e0266401.	2.5	2
18	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). <i>JAMA Oncology</i> , 2022, 8, 929.	7.1	4

#	ARTICLE	IF	CITATIONS
19	The fear of cancer recurrence and progression in patients with pancreatic cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 4879-4887.	2.2	4
20	Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study. <i>BMC Health Services Research</i> , 2022, 22, 527.	2.2	1
21	FOXO transcriptional activity is associated with response to chemoradiation in EAC. <i>Journal of Translational Medicine</i> , 2022, 20, 183.	4.4	1
22	Body Composition Is a Predictor for Postoperative Complications After Gastrectomy for Gastric Cancer: a Prospective Side Study of the LOGICA Trial. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1373-1387.	1.7	7
23	Effect of a pre-operative web-based dietary self-management intervention on patient satisfaction, body weight and quality of life of esophageal cancer patients: A prospective, observational study. <i>Clinical Nutrition Open Science</i> , 2022, 43, 42-55.	1.3	1
24	Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia. <i>Acta Oncologica</i> , 2022, 61, 849-855.	1.8	0
25	Turkish imams and their role in decision-making in palliative care: A Directed Content and Narrative analysis. <i>Palliative Medicine</i> , 2022, 36, 1006-1017.	3.1	3
26	Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. <i>Cancers</i> , 2022, 14, 2963.	3.7	0
27	Deep learning DCE-MRI parameter estimation: Application in pancreatic cancer. <i>Medical Image Analysis</i> , 2022, 80, 102512.	11.6	17
28	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211091.	3.2	3
29	Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. <i>Gastric Cancer</i> , 2022, 25, 906-915.	5.3	15
30	Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1657-1666.	1.7	5
31	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. <i>Journal of Medical Genetics</i> , 2021, 58, 369-377.	3.2	31
32	The role of hospital nurses in shared decision-making about life-prolonging treatment: A qualitative interview study. <i>Journal of Advanced Nursing</i> , 2021, 77, 296-307.	3.3	30
33	Cocoon vaccination for influenza in patients with a solid tumor: a retrospective study. <i>Supportive Care in Cancer</i> , 2021, 29, 3657-3666.	2.2	4
34	The effects of art therapy on anxiety, depression, and quality of life in adults with cancer: a systematic literature review. <i>Supportive Care in Cancer</i> , 2021, 29, 2289-2298.	2.2	34
35	Venous thromboembolism in cancer patients: a population-based cohort study. <i>Blood</i> , 2021, 137, 1959-1969.	1.4	277
36	Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. <i>Acta Oncologica</i> , 2021, 60, 497-504.	1.8	23

#	ARTICLE	IF	CITATIONS
37	Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer. , 2021, , 107-118.		2
38	Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study. <i>Cancers</i> , 2021, 13, 145.	3.7	9
39	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
40	Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 144-152.	4.9	15
41	Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis. <i>JAMA Oncology</i> , 2021, 7, 279.	7.1	56
42	10-year outcome of a randomized trial comparing neoadjuvant chemoradiotherapy and surgery with surgery alone for esophageal cancer (CROSS trial). <i>European Journal of Surgical Oncology</i> , 2021, 47, e31.	1.0	1
43	Readily available biomarkers predict poor survival in metastatic pancreatic cancer. <i>Biomarkers</i> , 2021, 26, 325-334.	1.9	8
44	Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. <i>Annals of Oncology</i> , 2021, 32, 360-367.	1.2	40
45	Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 91.	8.6	24
46	Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial. <i>British Journal of Surgery</i> , 2021, 108, 786-796.	0.3	12
47	Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1551-1560.	6.3	23
48	Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer. <i>Journal of Cancer Survivorship</i> , 2021, 15, 380-385.	2.9	4
49	OC-05 Risk of venous thromboembolism in cancer patients: a cohort study. <i>Thrombosis Research</i> , 2021, 200, S5.	1.7	1
50	Changes in hospital variation in the probability of receiving treatment with curative intent for esophageal and gastric cancer. <i>Cancer Epidemiology</i> , 2021, 71, 101897.	1.9	5
51	Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3784-3792.	7.0	30
52	Postoperative Complications and Long-Term Quality of Life After Multimodality Treatment for Esophageal Cancer: An Analysis of the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP). <i>Annals of Surgical Oncology</i> , 2021, 28, 7259-7276.	1.5	18
53	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. <i>Hpb</i> , 2021, 23, 1886-1896.	0.3	3
54	Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression. <i>Cancers</i> , 2021, 13, 2357.	3.7	2

#	ARTICLE	IF	CITATIONS
55	Digital Self-Management Support Tools in the Care Plan of Patients With Cancer: Review of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2021, 23, e20861.	4.3	18
56	The association between wearable activity monitor metrics and performance status in oncology: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 7085-7099.	2.2	7
57	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1995-2004.	1.6	291
58	Improved unsupervised physics-informed deep learning for intravoxel incoherent motion modeling and evaluation in pancreatic cancer patients. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 2250-2265.	3.0	41
59	Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. <i>Gastric Cancer</i> , 2021, 24, 1203-1212.	5.3	9
60	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.	1.0	5
61	Bereaved relatives' quality of life before and during the COVID-19 pandemic: Results of the prospective, multicenter, observational eQuiPe study. <i>Palliative Medicine</i> , 2021, 35, 1502-1507.	3.1	6
62	Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27824.	4.3	6
63	Presentation, Treatment, and Prognosis of Esophageal Carcinoma in A Nationwide Comparison of Sweden and the Netherlands. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, 743-750.	4.2	9
64	SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1045-1053.	4.9	1
65	Reply to C. Pãttgen et al and Y.-H. Lin et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01980.	1.6	1
66	Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). <i>Journal of Clinical Oncology</i> , 2021, 39, 2816-2824.	1.6	151
67	A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. <i>Cancer Treatment Reviews</i> , 2021, 99, 102249.	7.7	6
68	Evaluation of the Khorana, PROTECHT, and 5â€šNP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	3.8	14
69	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4869.	3.7	7
70	The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743907.	3.7	40
71	The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. <i>European Journal of Cancer</i> , 2021, 156, 60-69.	2.8	2
72	The role of transforming growth factor $\beta$ 2 in upper gastrointestinal cancers: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 100, 102285.	7.7	9

#	ARTICLE	IF	CITATIONS
73	Extensive diagnostic work-up for patients with carcinoma of unknown primary. Clinical and Experimental Metastasis, 2021, 38, 231-238.	3.3	6
74	Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. OncoImmunology, 2021, 10, 1954807.	4.6	17
75	SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 403-410.	4.9	7
76	<sup>18</sup> F-Fludeoxyglucoseâ€“Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer. JAMA Surgery, 2021, 156, e215340.	4.3	31
77	Perspective on the Immunotherapy of Esophageal Cancer. , 2021, , 43-56.		0
78	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 12-29.	6.3	25
79	Narrative meaning making and integration: Toward a better understanding of the way falling ill influences quality of life. Journal of Health Psychology, 2020, 25, 738-754.	2.3	34
80	Spiritual care by nurses in curative oncology: a mixedâ€“method study on patientsâ€™ perspectives and experiences. Scandinavian Journal of Caring Sciences, 2020, 34, 96-107.	2.1	12
81	Muscle Strength Is Associated With Muscle Mass in Patients With Esophageal Cancer Awaiting Surgery. Journal of Geriatric Physical Therapy, 2020, 43, 82-88.	1.1	3
82	Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. Hpb, 2020, 22, 405-414.	0.3	12
83	Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 4347-4357.	2.4	16
84	Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage Iâ€“IIIb compared with changes over a similar timeframe in women without cancer. Supportive Care in Cancer, 2020, 28, 1685-1693.	2.2	11
85	Heterogeneity of firstâ€“line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A realâ€“world evidence study. International Journal of Cancer, 2020, 146, 1889-1901.	5.1	29
86	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 146, 1445-1456.	5.1	67
87	Longâ€“Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy. World Journal of Surgery, 2020, 44, 838-848.	1.6	14
88	Rapid stromal remodeling by shortâ€“term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. Molecular Oncology, 2020, 14, 704-720.	4.6	7
89	Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. European Journal of Surgical Oncology, 2020, 46, 626-631.	1.0	9
90	From presentation to paper: Gender disparities in oncological research. International Journal of Cancer, 2020, 146, 3011-3021.	5.1	9

#	ARTICLE	IF	CITATIONS
91	Inherently decoupled $^1\text{H}$ antennas and $^{31}\text{P}$ loops for metabolic imaging of liver metastasis at 7 T. <i>NMR in Biomedicine</i> , 2020, 33, e4221.	2.8	7
92	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. <i>Hpb</i> , 2020, 22, 233-240.	0.3	66
93	Gastro-oesophageal junction: to FLOT or to CROSS?. <i>Acta Oncologica</i> , 2020, 59, 233-236.	1.8	7
94	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	1.6	44
95	Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial. <i>Oncologist</i> , 2020, 25, e578-e588.	3.7	37
96	Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial. <i>Cancer Medicine</i> , 2020, 9, 6609-6616.	2.8	8
97	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. <i>MAbs</i> , 2020, 12, 1795-1799.	5.2	11
98	Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103069.	4.4	32
99	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. <i>Cancer Medicine</i> , 2020, 9, 9385-9395.	2.8	12
100	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. <i>Pancreatology</i> , 2020, 20, 1723-1731.	1.1	9
101	Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study. <i>European Journal of Cancer</i> , 2020, 139, 107-118.	2.8	10
102	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. <i>JAMA Oncology</i> , 2020, 6, 1733.	7.1	85
103	1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry. <i>Annals of Oncology</i> , 2020, 31, S997-S998.	1.2	1
104	1458P Real-world treatment patterns of unresectable advanced or synchronous metastatic esophageal squamous cell cancer in a Western population. <i>Annals of Oncology</i> , 2020, 31, S914.	1.2	0
105	1465P A nationwide population-based study comparing treatment patterns and outcomes in synchronous versus metachronous metastatic esophageal and gastric adenocarcinoma. <i>Annals of Oncology</i> , 2020, 31, S917.	1.2	0
106	1526P First and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort. <i>Annals of Oncology</i> , 2020, 31, S939-S940.	1.2	3
107	1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. <i>Annals of Oncology</i> , 2020, 31, S928-S929.	1.2	8
108	Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. <i>Biomedicines</i> , 2020, 8, 444.	3.2	9

#	ARTICLE	IF	CITATIONS
109	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.6	19
110	Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?. <i>Lancet Oncology</i> , The, 2020, 21, 743-745.	10.7	6
111	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	7.4	67
112	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. <i>Annals of Surgery</i> , 2020, 271, e102-e104.	4.2	43
113	Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial. <i>European Journal of Cancer</i> , 2020, 130, 146-154.	2.8	17
114	Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization. <i>PLoS ONE</i> , 2020, 15, e0234543.	2.5	12
115	Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 756-767.	7.3	34
116	Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. <i>Scientific Reports</i> , 2020, 10, 337.	3.3	46
117	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. <i>Acta Oncol<sup>3</sup>gica</i> , 2020, 59, 705-712.	1.8	9
118	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , 2020, 25, e634-e643.	3.7	33
119	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. <i>Annals of Surgical Oncology</i> , 2020, 27, 2516-2524.	1.5	36
120	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	5.3	16
121	Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods. <i>Quality of Life Research</i> , 2020, 29, 1747-1766.	3.1	25
122	MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2020, 86, 102024.	7.7	90
123	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. <i>Acta Oncol<sup>3</sup>gica</i> , 2020, 59, 895-903.	1.8	10
124	High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. <i>EMBO Reports</i> , 2020, 21, e48780.	4.5	29
125	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. <i>Molecular Oncology</i> , 2020, 14, 2176-2189.	4.6	23
126	Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. <i>Trials</i> , 2020, 21, 334.	1.6	14

#	ARTICLE	IF	CITATIONS
127	External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. <i>Cancers</i> , 2020, 12, 834.	3.7	6
128	Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. <i>British Journal of Surgery</i> , 2020, 107, 1053-1061.	0.3	26
129	Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.4	18
130	A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 281-281.	1.6	41
131	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 704-711.	4.9	14
132	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1354-1363.	4.9	11
133	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 684.	2.8	10
134	Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. <i>Cancers</i> , 2019, 11, 871.	3.7	0
135	Vlogging at the end of life. <i>Lancet Oncology</i> , The, 2019, 20, 911-912.	10.7	1
136	Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. <i>BMC Cancer</i> , 2019, 19, 662.	2.6	62
137	Living with advanced cancer: Rich Pictures as a means for health care providers to explore the experiences of advanced cancer patients. <i>Cancer Medicine</i> , 2019, 8, 4957-4966.	2.8	10
138	The association between wearable device physical activity metrics and performance status in oncology: A systematic review. <i>Annals of Oncology</i> , 2019, 30, v583.	1.2	0
139	Associations between sex, age and spiritual well-being scores on the EORTC QLQ-C15WB32 for patients receiving palliative care for cancer: A further analysis of data from an international validation study. <i>European Journal of Cancer Care</i> , 2019, 28, e13145.	1.5	16
140	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. <i>Science Advances</i> , 2019, 5, eaax2770.	10.3	81
141	The Use of (Network) Meta-Analysis in Clinical Oncology. <i>Frontiers in Oncology</i> , 2019, 9, 822.	2.8	38
142	Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy. <i>Nutrition and Cancer</i> , 2019, 71, 756-766.	2.0	8
143	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 199-207.	8.1	393
144	Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 199-206.	7.3	86

#	ARTICLE	IF	CITATIONS
145	Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2237-2242.	7.1	128
146	Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. <i>British Journal of Cancer</i> , 2019, 121, 34-36.	6.4	16
147	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984123.	3.2	35
148	Postoperative surveillance of pancreatic cancer patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1770-1777.	1.0	32
149	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). <i>Cancers</i> , 2019, 11, 827.	3.7	6
150	Contradiction between amide $\epsilon$ -CEST signal and pH in breast cancer explained with metabolic MRI. <i>NMR in Biomedicine</i> , 2019, 32, e4110.	2.8	20
151	A novel amplitude binning strategy to handle irregular breathing during 4DMRI acquisition: improved imaging for radiotherapy purposes. <i>Radiation Oncology</i> , 2019, 14, 80.	2.7	10
152	Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2792-2803.	5.1	23
153	Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. <i>Hpb</i> , 2019, 21, 1385-1392.	0.3	16
154	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 530.	3.7	17
155	TOXview: a novel graphical presentation of cancer treatment toxicity profiles. <i>Acta Oncologica</i> , 2019, 58, 1138-1148.	1.8	9
156	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 588.	3.7	42
157	Principal component analysis for fast and model-free denoising of multi b-value diffusion-weighted MR images. <i>Physics in Medicine and Biology</i> , 2019, 64, 105015.	3.0	22
158	Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T. <i>NMR in Biomedicine</i> , 2019, 32, e4086.	2.8	20
159	Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. <i>Gastric Cancer</i> , 2019, 22, 1263-1273.	5.3	45
160	Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1926-1933.	1.0	11
161	Cardiac molecular pathways influenced by doxorubicin treatment in mice. <i>Scientific Reports</i> , 2019, 9, 2514.	3.3	22
162	The dynamics in health-related quality of life of patients with stable coronary artery disease were revealed: a network analysis. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 116-123.	5.0	11

#	ARTICLE	IF	CITATIONS
163	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	3.7	20
164	Tragedy as Contingency Acknowledgement: Towards a Practical Religious-Scientific Theory. <i>Journal of Empirical Theology</i> , 2019, 32, 232-250.	0.8	3
165	Modes of Narrative Integration of Experiences of Contingency in Highly Sensitive Children: a Qualitative Pilot Study. <i>Journal of Empirical Theology</i> , 2019, 32, 211-231.	0.8	0
166	P40 CONDITIONAL SURVIVAL AFTER CURATIVE TREATMENT OF ESOPHAGEAL CANCER. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	0
167	P14 THE IMPACT OF TRANSTHORACIC AND TRANSHIATAL ESOPHAGECTOMY ON LONG-TERM QUALITY OF LIFE ACCORDING TO EORTC QLQ-C30 AND EORTC QLQ-OG25 QUESTIONNAIRES. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	0
168	Reconstructing Disruptive Life Events Using the RE-LIFE Questionnaire: Further Validation of the "Narrative Meaning Making of Life Events" Model Using Multiple Mediation Analysis. <i>Journal of Empirical Theology</i> , 2019, 32, 251-280.	0.8	1
169	Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial. <i>Oncologist</i> , 2019, 24, 259-265.	3.7	36
170	Cutaneous Toxicity After Chemoradiotherapy and PD-1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. <i>Oncologist</i> , 2019, 24, e149-e153.	3.7	5
171	P12 LONG-TERM QUALITY OF LIFE AFTER TOTAL GASTRECTOMY VERSUS IVOR LEWIS ESOPHAGECTOMY. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	0
172	P13 DIFFERENCE IN LONG-TERM QUALITY OF LIFE BETWEEN MCKEOWN AND IVOR LEWIS ESOPHAGECTOMY. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	0
173	Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage III breast cancer receiving chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 475-481.	2.5	26
174	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. <i>European Journal of Cancer</i> , 2019, 106, 99-105.	2.8	30
175	Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by <sup>1</sup> H MRS. <i>NMR in Biomedicine</i> , 2019, 32, e4035.	2.8	5
176	A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol. <i>BMC Cancer</i> , 2019, 19, 7.	2.6	13
177	Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid. <i>Patient Education and Counseling</i> , 2019, 102, 916-923.	2.2	14
178	The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. <i>Cancers</i> , 2019, 11, 80.	3.7	30
179	Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 275-282.	2.5	56
180	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019, 144, 1275-1283.	5.1	36

#	ARTICLE	IF	CITATIONS
181	An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study). <i>Palliative Medicine</i> , 2019, 33, 221-231.	3.1	7
182	Relationship between physicians' death anxiety and medical communication and decision-making: A systematic review. <i>Patient Education and Counseling</i> , 2019, 102, 266-274.	2.2	42
183	Low reported taste function is associated with low preference for high protein products in advanced oesophagogastric cancer patients undergoing palliative chemotherapy. <i>Clinical Nutrition</i> , 2019, 38, 472-475.	5.0	7
184	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). <i>Annals of Surgery</i> , 2019, 270, 158-164.	4.2	44
185	Tailored Web-Based Information for Younger and Older Patients with Cancer: Randomized Controlled Trial of a Preparatory Educational Intervention on Patient Outcomes. <i>Journal of Medical Internet Research</i> , 2019, 21, e14407.	4.3	22
186	Trends in treatment and overall survival among patients with proximal esophageal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 6835-6846.	3.3	13
187	Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 1383-1392.	2.2	8
188	Relating to the Experience of Contingency in Patients With Advanced Cancer: An Interview Study in U.S. Patients. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 913-921.	1.2	6
189	Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. <i>Hpb</i> , 2018, 20, 605-611.	0.3	69
190	Taste and smell perception and quality of life during and after systemic therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 27-34.	2.5	45
191	Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma. <i>Magnetic Resonance Imaging</i> , 2018, 50, 1-9.	1.8	16
192	The Dutch Pancreas Biobank Within the Parelsoer Institute. <i>Pancreas</i> , 2018, 47, 495-501.	1.1	8
193	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
194	Are the effects of cognitive behavior therapy for severe fatigue in cancer survivors sustained up to 14 years after therapy?. <i>Journal of Cancer Survivorship</i> , 2018, 12, 519-527.	2.9	16
195	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 616-628.	10.7	397
196	Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. <i>International Journal of Cancer</i> , 2018, 143, 438-448.	5.1	22
197	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. <i>Gastric Cancer</i> , 2018, 21, 183-195.	5.3	15
198	Evaluation of PET and laparoscopy in STaging advanced gastric cancer: a multicenter prospective study (PLASTIC-study). <i>BMC Cancer</i> , 2018, 18, 450.	2.6	28

#	ARTICLE	IF	CITATIONS
199	Response to letter to the editor. <i>Supportive Care in Cancer</i> , 2018, 26, 1689-1689.	2.2	0
200	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. <i>Acta Oncologica</i> , 2018, 57, 195-202.	1.8	55
201	Altered food preferences and chemosensory perception during chemotherapy in breast cancer patients: A longitudinal comparison with healthy controls. <i>Food Quality and Preference</i> , 2018, 63, 135-143.	4.6	26
202	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. <i>International Journal of Hyperthermia</i> , 2018, 34, 969-979.	2.5	41
203	Hospital of Diagnosis Influences the Probability of Receiving Curative Treatment for Esophageal Cancer. <i>Annals of Surgery</i> , 2018, 267, 303-310.	4.2	25
204	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 268-275.	1.6	91
205	Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 1511-1521.	1.4	3
206	PS02.084: PROSPECTIVE EVALUATION OF 18F-FDG PET-CT AFTER NEOADJUVANT CHEMORADIO THERAPY FOR DETECTING LYMPH NODE METASTASES NEAR THE CELIAC TRUNK IN PATIENTS WITH ESOPHAGEAL CANCER. <i>Ecological Management and Restoration</i> , 2018, 31, 144-144.	0.4	0
207	The efficacy and safety of (neo)adjuvant therapy for gastric cancer: A network meta-analysis. <i>Annals of Oncology</i> , 2018, 29, viii227.	1.2	0
208	PS02.140: OUTCOMES OF SALVAGE SURGERY IN PATIENTS WITH RECURRENT ESOPHAGEAL CANCER AFTER DEFINITIVE CHEMORADIO THERAPY. <i>Ecological Management and Restoration</i> , 2018, 31, 160-160.	0.4	0
209	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. <i>PLoS ONE</i> , 2018, 13, e0207362.	2.5	31
210	ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. <i>Oncogenesis</i> , 2018, 7, 87.	4.9	40
211	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 45-52.	2.4	13
212	The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 53-59.	2.4	12
213	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 214-226.	2.8	28
214	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. <i>Acta Oncologica</i> , 2018, 57, 1655-1662.	1.8	70
215	Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. <i>Acta Oncologica</i> , 2018, 57, 1599-1604.	1.8	13
216	Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 34.	3.7	35

#	ARTICLE	IF	CITATIONS
217	PS02.237: IDENTIFICATION OF THREE DISTINCT BIOLOGICAL SUBTYPES IN ESOPHAGEAL AND JUNCTIONAL ADENOCARCINOMA BY RNA SEQUENCING. <i>Ecological Management and Restoration</i> , 2018, 31, 189-189.	0.4	0
218	Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas. <i>Annals of Oncology</i> , 2018, 29, viii211.	1.2	2
219	Who should provide care for patients receiving palliative chemotherapy? A qualitative study among Dutch general practitioners and oncologists. <i>Scandinavian Journal of Primary Health Care</i> , 2018, 36, 437-445.	1.5	4
220	Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. <i>BMC Cancer</i> , 2018, 18, 1006.	2.6	54
221	A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13281.	3.3	28
222	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , 2018, 18, 877.	2.6	115
223	Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial. <i>Cancer Investigation</i> , 2018, 36, 371-377.	1.3	3
224	Multidrug-resistant transporter expression does not always result in drug resistance. <i>Cancer Science</i> , 2018, 109, 3360-3362.	3.9	2
225	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 965-974.	10.7	211
226	Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. <i>Acta Oncologica</i> , 2018, 57, 1185-1191.	1.8	15
227	Group medical consultations (GMCs) and tablet-based online support group sessions in the follow-up of breast cancer: A multicenter randomized controlled trial. <i>Breast</i> , 2018, 40, 181-188.	2.2	26
228	Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients. <i>PLoS ONE</i> , 2018, 13, e0194590.	2.5	44
229	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1052-1062.	0.8	20
230	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. <i>Acta Oncologica</i> , 2018, 57, 1475-1481.	1.8	58
231	Stroma and tumor protein landscapes of laser microdissected pancreatic cancer predict poor prognosis. <i>Pancreatology</i> , 2018, 18, S144-S145.	1.1	0
232	A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHOICE): study protocol. <i>BMC Cancer</i> , 2018, 18, 55.	2.6	31
233	Muslim physicians and palliative care: attitudes towards the use of palliative sedation. <i>Supportive Care in Cancer</i> , 2018, 26, 3701-3710.	2.2	11
234	Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. <i>Biomedical Optics Express</i> , 2018, 9, 4196.	2.9	4

#	ARTICLE	IF	CITATIONS
235	Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second Opinions. <i>JAMA Oncology</i> , 2018, 4, 1425.	7.1	5
236	Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0192310.	2.5	43
237	The stereotypicality of symptomatic and pragmatic argumentation in consultations about palliative systemic treatment for advanced cancer. <i>Journal of Argumentation in Context</i> , 2018, 7, 181-203.	0.4	5
238	Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis. <i>Oncotarget</i> , 2018, 9, 28445-28455.	1.8	7
239	The dynamics of HER2 status in esophageal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 26787-26799.	1.8	17
240	Commentary on "A pragma-dialectical perspective on obstacles to shared decision-making". <i>Journal of Argumentation in Context</i> , 2018, 7, 177-180.	0.4	0
241	Clinical and biological effects of demethylating agents on solid tumours " A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 54, 10-23.	7.7	108
242	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2282-2290.	1.5	39
243	Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. <i>European Journal of Cancer</i> , 2017, 78, 28-36.	2.8	24
244	How long do I have? Observational study on communication about life expectancy with advanced cancer patients. <i>Patient Education and Counseling</i> , 2017, 100, 1820-1827.	2.2	46
245	The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. <i>Journal of Psychosomatic Research</i> , 2017, 98, 40-46.	2.6	222
246	Spiritual care by nurses in curative cancer care: Protocol for a national, multicentre, mixed method study. <i>Journal of Advanced Nursing</i> , 2017, 73, 2201-2207.	3.3	13
247	Mindfulness-based stress reduction for breast cancer patients: a mixed method study on what patients experience as a suitable stage to participate. <i>Supportive Care in Cancer</i> , 2017, 25, 3067-3074.	2.2	22
248	Stromal SPOCK1 supports invasive pancreatic cancer growth. <i>Molecular Oncology</i> , 2017, 11, 1050-1064.	4.6	27
249	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2734-2743.	1.5	70
250	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. <i>BMJ Open</i> , 2017, 7, e014961.	1.9	69
251	Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients' preferences. <i>Palliative Medicine</i> , 2017, 31, 625-633.	3.1	50
252	On the Receiving End of Autonomy and Law. <i>Oncologist</i> , 2017, 22, 1143-1145.	3.7	0

#	ARTICLE	IF	CITATIONS
253	Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. <i>Seminars in Cancer Biology</i> , 2017, 44, 153-169.	9.6	68
254	Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. <i>Acta Oncologica</i> , 2017, 56, 923-930.	1.8	23
255	Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. <i>Gastroenterology</i> , 2017, 153, 63-76.e14.	1.3	25
256	Differences in dietary intake during chemotherapy in breast cancer patients compared to women without cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 2581-2591.	2.2	61
257	Molecular Tumor Boards: current practice and future needs. <i>Annals of Oncology</i> , 2017, 28, 3070-3075.	1.2	112
258	Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3647-3657.	1.5	6
259	Modes of relating to contingency: An exploration of experiences in advanced cancer patients. <i>Palliative and Supportive Care</i> , 2017, 15, 444-453.	1.0	18
260	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. <i>Scientific Reports</i> , 2017, 7, 7142.	3.3	20
261	The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancer. <i>European Journal of Cancer Care</i> , 2017, 26, e12697.	1.5	24
262	Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 394-403.	7.4	45
263	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. <i>Drug Delivery</i> , 2017, 24, 1801-1810.	5.7	5
264	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 2840-2849.	2.8	41
265	Neoadjuvant chemotherapy in oesophageal adenocarcinoma. <i>Lancet Oncology</i> , The, 2017, 18, e639.	10.7	3
266	Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. <i>Acta Oncologica</i> , 2017, 56, 33-38.	1.8	15
267	COnsensus statement on mandatory measurements in PANcreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT). <i>Annals of Oncology</i> , 2017, 28, v255.	1.2	0
268	A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, v260.	1.2	4
269	Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis. <i>Annals of Oncology</i> , 2017, 28, v229.	1.2	1
270	Prognostic and predictive factors for overall survival (OS) in metastatic esophagogastric cancer (EGC): A meta-analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 4048-4048.	1.6	1

#	ARTICLE	IF	CITATIONS
271	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	1.8	13
272	A 52-year-old oncology patient with acute severe abdominal pain. <i>Netherlands Journal of Medicine</i> , 2017, 75, 359.	0.5	0
273	Dynamics of the HER2 receptor in esophageal adenocarcinoma: New opportunities for targeted therapy. <i>Annals of Oncology</i> , 2016, 27, vi227.	1.2	0
274	ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. <i>Oncotarget</i> , 2016, 7, 10243-10254.	1.8	27
275	Minimizing the Acquisition Time for Intravoxel Incoherent Motion Magnetic Resonance Imaging Acquisitions in the Liver and Pancreas. <i>Investigative Radiology</i> , 2016, 51, 211-220.	6.2	37
276	Revisiting the Potential of Alternating Repetition Time Balanced Steady-State Free Precession Imaging of the Abdomen at 3 T. <i>Investigative Radiology</i> , 2016, 51, 560-568.	6.2	4
277	Quantitative assessment of biliary stent artifacts on MR images: Potential implications for target delineation in radiotherapy. <i>Medical Physics</i> , 2016, 43, 5603-5615.	3.0	7
278	Professional identity at stake: a phenomenological analysis of spiritual counselors's experiences working with a structured model to provide care to palliative cancer patients. <i>Supportive Care in Cancer</i> , 2016, 24, 3111-8.	2.2	7
279	Oncologists' non-verbal behavior and analog patients' recall of information. <i>Acta Oncologica</i> , 2016, 55, 671-679.	1.8	19
280	Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1353-1360.	2.5	42
281	Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013. <i>Acta Oncologica</i> , 2016, 55, 1161-1167.	1.8	7
282	Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2016, 18, 559-566.	0.3	23
283	Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions. <i>NMR in Biomedicine</i> , 2016, 29, 1526-1535.	2.8	1
284	The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw166.	6.3	88
285	Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 551-563.	2.4	12
286	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 439-456.	5.9	39
287	PO-0706: Supraclavicular lymphnode disease is not an independent prognostic factor in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, S329-S330.	0.6	0
288	Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. <i>British Journal of Surgery</i> , 2016, 103, 1658-1664.	0.3	17

#	ARTICLE	IF	CITATIONS
289	Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 684-690.	1.7	14
290	The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. <i>Cancer Medicine</i> , 2016, 5, 2825-2831.	2.8	57
291	Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction. <i>Annals of Surgery</i> , 2016, 264, 847-853.	4.2	37
292	Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review. <i>Physical Therapy</i> , 2016, 96, 1965-1981.	2.4	133
293	A qualitative study on mindfulness-based stress reduction for breast cancer patients: how women experience participating with fellow patients. <i>Supportive Care in Cancer</i> , 2016, 24, 1813-1820.	2.2	32
294	Insulin-like growth factor 1 receptor expression and IGF1R 3129G>>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	5.0	30
295	The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study. <i>Supportive Care in Cancer</i> , 2016, 24, 3119-26.	2.2	23
296	Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. <i>European Journal of Cancer</i> , 2016, 57, 68-77.	2.8	33
297	S-1 with leucovorin and oxaliplatin for advanced gastric cancer. <i>Lancet Oncology</i> , The, 2016, 17, e41.	10.7	4
298	The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. <i>Gastric Cancer</i> , 2016, 19, 696-712.	5.3	35
299	Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. <i>Acta Oncologica</i> , 2016, 55, 423-429.	1.8	12
300	Peer support and additional information in group medical consultations (GMCs) for BRCA1/2 mutation carriers: A randomized controlled trial. <i>Acta Oncologica</i> , 2016, 55, 178-187.	1.8	5
301	Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215801.	0.5	3
302	Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15738-e15738.	1.6	0
303	CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study. <i>Chinese Clinical Oncology</i> , 2016, 5, 13.	1.2	4
304	Decision Making About Treatment for Advanced Cancer. <i>JAMA Oncology</i> , 2015, 1, 1169.	7.1	6
305	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 501-507.	2.0	13
306	Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. <i>Ecological Management and Restoration</i> , 2015, 28, 453-459.	0.4	73

#	ARTICLE	IF	CITATIONS
307	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0117745.	2.5	32
308	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0120823.	2.5	33
309	18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making. <i>PLoS ONE</i> , 2015, 10, e0133690.	2.5	24
310	New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. <i>Biomarkers</i> , 2015, 20, 143-148.	1.9	47
311	Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. <i>Journal of Translational Medicine</i> , 2015, 13, 115.	4.4	60
312	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 94-99.	0.6	44
313	Burden of spousal caregivers of stage II and III esophageal cancer survivors 3 years after treatment with curative intent. <i>Supportive Care in Cancer</i> , 2015, 23, 3589-3598.	2.2	29
314	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
315	The Role of Central and Peripheral Muscle Fatigue in Postcancer Fatigue: A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 173-182.	1.2	33
316	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 91-95.	0.6	16
317	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 97-114.	5.9	69
318	Group medical consultations in the follow-up of breast cancer: a randomized feasibility study. <i>Journal of Cancer Survivorship</i> , 2015, 9, 450-461.	2.9	8
319	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1090-1098.	10.7	1,861
320	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1634-1640.	3.3	2
321	The interweaving of pharmaceutical and medical expectations as dynamics of micro-pharmaceuticalisation: Advanced-stage cancer patients' hope in medicines alongside trust in professionals. <i>Social Science and Medicine</i> , 2015, 131, 313-321.	3.8	20
322	Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. <i>Acta Oncologica</i> , 2015, 54, 403-410.	1.8	30
323	Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research and Treatment</i> , 2015, 149, 461-466.	2.5	16
324	A qualitative analysis of experiences of patients with metastatic breast cancer participating in a mindfulness-based intervention. <i>Palliative Medicine</i> , 2015, 29, 182-183.	3.1	6

#	ARTICLE	IF	CITATIONS
325	All eyes on the patient: the influence of oncologists' nonverbal communication on breast cancer patients' trust. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 161-171.	2.5	53
326	Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 429-441.	5.9	53
327	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 957-967.	2.3	25
328	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. <i>Annals of Surgical Oncology</i> , 2015, 22, 766-771.	1.5	17
329	Inflammatory breast cancer: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 116-126.	4.4	113
330	Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. <i>International Journal of Cancer</i> , 2015, 136, 91-97.	5.1	16
331	Selective Attention and Fear of Cancer Recurrence in Breast Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2015, 49, 66-73.	2.9	18
332	Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. <i>JMIR Research Protocols</i> , 2015, 4, e79.	1.0	69
333	How can communication by oncologists enhance patients' trust? An experimental study. <i>Annals of Oncology</i> , 2014, 25, 896-901.	1.2	62
334	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. <i>Molecular Pharmaceutics</i> , 2014, 11, 4249-4257.	4.6	8
335	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). <i>Annals of Oncology</i> , 2014, 25, 998-1004.	1.2	33
336	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 237-245.	0.8	24
337	Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency. <i>Journal of Cell Science</i> , 2014, 128, 129-39.	2.0	24
338	To Treat or Not To Treat: Who Should Decide?. <i>Oncologist</i> , 2014, 19, 433-436.	3.7	7
339	Quantification of Patient-Specific Assay Interference in Different Formats of Enzyme-Linked Immunoassays for Therapeutic Monoclonal Antibodies. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 765-770.	2.0	8
340	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. <i>Nuclear Medicine Communications</i> , 2014, 35, 472-477.	1.1	7
341	The Cancer Worry Scale. <i>Cancer Nursing</i> , 2014, 37, E44-E50.	1.5	170
342	Treatment Related Impairments in Arm and Shoulder in Patients with Breast Cancer: A Systematic Review. <i>PLoS ONE</i> , 2014, 9, e96748.	2.5	210

#	ARTICLE	IF	CITATIONS
343	Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. <i>BMC Cancer</i> , 2014, 14, 56.	2.6	24
344	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 175-185.	5.0	7
345	Early myocardial deformation abnormalities in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 127-135.	2.5	12
346	Targeted therapy for advanced esophagogastric adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 68-76.	4.4	22
347	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4044-4044.	1.6	0
348	Distress screening remains important during follow-up after primary breast cancer treatment. <i>Supportive Care in Cancer</i> , 2013, 21, 2107-2115.	2.2	71
349	The role of physical activity and physical fitness in postcancer fatigue: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2013, 21, 2279-2288.	2.2	37
350	Survival After Recurrent Esophageal Carcinoma Has Not Improved Over the Past 18 Years. <i>Annals of Surgical Oncology</i> , 2013, 20, 2693-2698.	1.5	54
351	Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. <i>European Radiology</i> , 2013, 23, 748-756.	4.5	65
352	Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2013, 31, 4290-4296.	1.6	40
353	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. <i>European Journal of Radiology</i> , 2013, 82, 1416-1422.	2.6	18
354	Maximal exercise performance in patients with postcancer fatigue. <i>Supportive Care in Cancer</i> , 2013, 21, 439-447.	2.2	5
355	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. <i>Investigational New Drugs</i> , 2013, 31, 881-890.	2.6	7
356	Screening Patient Spirituality and Spiritual Needs in Oncology Nursing. <i>Holistic Nursing Practice</i> , 2013, 27, 207-216.	0.7	19
357	Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients. <i>Cancer Nursing</i> , 2013, 36, 52-59.	1.5	33
358	Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2013, 31, 4283-4289.	1.6	35
359	Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. <i>International Journal of Cancer</i> , 2013, 133, 307-314.	5.1	49
360	Reproducibility and biological basis of in vivo $T_2^*$ magnetic resonance imaging of liver metastasis of colorectal cancer. <i>Magnetic Resonance in Medicine</i> , 2013, 70, 1145-1152.	3.0	3

#	ARTICLE	IF	CITATIONS
361	Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 151-160.	1.8	11
362	NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)â€™A Dutch Breast Cancer Trialistsâ€™ Group (BOOG) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1028-1028.	1.6	2
363	Magnetic Resonance Spectroscopic Imaging and Volumetric Measurements of the Brain in Patients with Postcancer Fatigue: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e74638.	2.5	7
364	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 146-153.	5.0	66
365	Comparison of Attitudes of Guilt and Forgiveness in Cancer Patients Without Evidence of Disease and Advanced Cancer Patients in a Palliative Care Setting. <i>Cancer Nursing</i> , 2012, 35, 483-492.	1.5	9
366	Palliative Care for an Islamic Patient: Changing Frameworks. <i>Journal of Palliative Medicine</i> , 2012, 15, 1053-1055.	1.1	10
367	Axillary Recurrence After a Tumor-Positive Sentinel Lymph Node Biopsy Without Axillary Treatment: A Review of the Literature. <i>Annals of Surgical Oncology</i> , 2012, 19, 4140-4149.	1.5	48
368	Optimization of IGF-1R SPECT/CT Imaging Using <sup>111</sup> In-Labeled F(abâ€™ <sub>2</sub> ) and Fab Fragments of the Monoclonal Antibody R1507. <i>Molecular Pharmaceutics</i> , 2012, 9, 2314-2321.	4.6	35
369	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 194-207.	4.4	61
370	Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 252-260.	4.4	36
371	Letter to the Editor: Interobserver Variability of Heart-to-Mediastinum Ratio in I-123 MIBG Sympathetic Imaging. <i>Current Cardiology Reports</i> , 2012, 14, 389-390.	2.9	3
372	Encouraging results in older patients receiving chemotherapy: A retrospective analysis of treatment guideline adherence in daily practice. <i>Geriatrics and Gerontology International</i> , 2012, 12, 80-85.	1.5	5
373	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3035-3035.	1.6	0
374	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9070-9070.	1.6	0
375	Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. <i>Acta OncolÃ³gica</i> , 2011, 50, 462-465.	1.8	14
376	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. <i>Clinical Colorectal Cancer</i> , 2011, 10, E1-E5.	2.3	16
377	Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. <i>European Journal of Radiology</i> , 2011, 80, 655-661.	2.6	6
378	The <i>CYP2C19*2</i> genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. <i>Pharmacogenomics</i> , 2011, 12, 1137-1146.	1.3	44

#	ARTICLE	IF	CITATIONS
379	Constitutive expression of $\gamma$ -H2AX has prognostic relevance in triple negative breast cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 39-45.	0.6	74
380	<i>In vivo</i> magnetic resonance spectroscopy of liver tumors and metastases. <i>World Journal of Gastroenterology</i> , 2011, 17, 5133.	3.3	39
381	Coping, Quality of Life, Depression, and Hopelessness in Cancer Patients in a Curative and Palliative, End-of-Life Care Setting. <i>Cancer Nursing</i> , 2011, 34, 302-314.	1.5	51
382	Time Perception of Cancer Patients Without Evidence of Disease and Advanced Cancer Patients in a Palliative, End-of-Life-Care Setting. <i>Cancer Nursing</i> , 2011, 34, 453-463.	1.5	23
383	Perspectives on Death and an Afterlife in Relation to Quality of Life, Depression, and Hopelessness in Cancer Patients Without Evidence of Disease and Advanced Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2011, 41, 1048-1059.	1.2	14
384	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. <i>BMC Women's Health</i> , 2011, 11, 39.	2.0	14
385	Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. <i>Cancer</i> , 2011, 117, 3670-3681.	4.1	57
386	When Hope Is All There Is Left. <i>Oncologist</i> , 2011, 16, 914-916.	3.7	5
387	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. <i>Clinical Cancer Research</i> , 2011, 17, 7693-7703.	7.0	39
388	Assessment of Blood Hemodynamics by USPIO-Induced R1 Changes in MRI of Murine Colon Carcinoma. <i>Applied Magnetic Resonance</i> , 2010, 38, 349-360.	1.2	6
389	Images of God in Relation to Coping Strategies of Palliative Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 495-501.	1.2	30
390	Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041). <i>Clinical Cancer Research</i> , 2010, 16, 1315-1323.	7.0	39
391	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1565-1572.	5.0	84
392	Triple-negative breast cancer: Present challenges and new perspectives. <i>Molecular Oncology</i> , 2010, 4, 209-229.	4.6	252
393	Religious and Nonreligious Coping among Cancer Patients. <i>Journal of Empirical Theology</i> , 2009, 22, 195-215.	0.8	4
394	Dying at the Right Time: A Modern Dilemma. <i>Oncologist</i> , 2009, 14, 642-643.	3.7	3
395	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	5.0	29
396	Feasibility of concurrent dual contrast enhancement using CEST contrast agents and superparamagnetic iron oxide particles. <i>Magnetic Resonance in Medicine</i> , 2009, 61, 970-974.	3.0	33

#	ARTICLE	IF	CITATIONS
397	Ischemic neuropathy and rhabdomyolysis as presenting symptoms of postpartum cardiomyopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 458-460.	2.1	0
398	Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 309-321.	7.7	151
399	Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes. <i>Cancer Research</i> , 2009, 69, 3180-3187.	0.9	83
400	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 550-557.	1.1	16
401	The diagnostic hurdle of an elderly male with bone pain: how 18F-FDG-PET led to diagnosis of a leiomyosarcoma of the adrenal gland. <i>Anticancer Research</i> , 2009, 29, 469-72.	1.1	11
402	Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. <i>Annals of Oncology</i> , 2008, 19, 348-352.	1.2	98
403	A patient with abdominal pain and a rash. <i>Netherlands Journal of Medicine</i> , 2008, 66, 48-9.	0.5	0
404	Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. <i>NMR in Biomedicine</i> , 2007, 20, 128-140.	2.8	49
405	Artificial reporter gene providing MRI contrast based on proton exchange. <i>Nature Biotechnology</i> , 2007, 25, 217-219.	17.5	379
406	Carbogen Breathing Differentially Enhances Blood Plasma Volume and 5-Fluorouracil Uptake in Two Murine Colon Tumor Models with a Distinct Vascular Structure. <i>Neoplasia</i> , 2006, 8, 477-487.	5.3	17
407	Assessment of absolute blood volume in carcinoma by USPIO contrast-enhanced MRI. <i>Magnetic Resonance Imaging</i> , 2006, 24, 279-286.	1.8	25
408	Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. <i>Investigational New Drugs</i> , 2006, 24, 27-36.	2.6	43
409	A patient with swollen ears and ECG abnormalities. <i>Netherlands Journal of Medicine</i> , 2006, 64, 130, 132.	0.5	0
410	Monitoring fluoropyrimidine metabolism in solid tumors with in vivo 19F magnetic resonance spectroscopy. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 321-343.	4.4	34
411	Pitfall in HPLC Assay for Urinary Metanephrines: An Unusual Type of Interference Caused by Methenamine Intake. <i>Clinical Chemistry</i> , 2004, 50, 1097-1099.	3.2	13
412	Systemic treatment of advanced colorectal carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 283-289.	1.6	13
413	5-FU-induced peripheral neuropathy: a rare complication of a well-known drug. <i>Anticancer Research</i> , 2003, 23, 647-8.	1.1	7
414	In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. <i>Cancer Research</i> , 2003, 63, 7609-12.	0.9	28

#	ARTICLE	IF	CITATIONS
415	Single-centre experience with tunnelled central venous catheters in 150 cancer patients. Netherlands Journal of Medicine, 2002, 60, 397-401.	0.5	19
416	Guillain-Barré syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. Nephrology Dialysis Transplantation, 2001, 16, 840-842.	0.7	18